Prostaglandin D₂: a Dominant Mediator of Aspirin-exacerbated Respiratory Disease

Overview

Journal J Allergy Clin Immunol

Specialty Allergy & Immunology

Date 2014 Sep 15

PMID 25218285

Citations 101

Authors

Katherine N Cahill

Jillian C Bensko

Joshua A Boyce

Tanya M Laidlaw

Affiliations

Soon will be listed here.

Abstract

Background: Aspirin desensitization followed by high-dose aspirin therapy is routinely performed for patients with aspirin-exacerbated respiratory disease (AERD). Little is known about the contributions of mediators other than cysteinyl leukotrienes to aspirin reactions and to the therapeutic benefit of high-dose aspirin therapy.

Objective: We investigated differences in urinary eicosanoid metabolite levels and blood eosinophil counts in patients with AERD who tolerate and those who fail aspirin desensitization and also in patients with AERD who were successfully treated with high-dose aspirin therapy.

Methods: Twenty-nine patients with AERD were stratified into those who tolerated aspirin desensitization (group I) and those who did not (group II). Urine was analyzed for eicosanoid metabolites at baseline, during aspirin reactions, and during high-dose aspirin therapy. Blood was analyzed for cell differentials at baseline and during aspirin therapy.

Results: Basal prostaglandin D2 metabolite (PGD-M; 13.6 ± 2.7 vs 7.0 ± 0.8 pmol/mg creatinine [Cr], P < .05) and thromboxane metabolite (TX-M; 1.4 ± 0.3 vs 0.9 ± 0.1 pmol/mg Cr, P < .01) levels were higher in group II than in group I. During aspirin reactions, PGD-M levels remained unchanged, whereas TX-M levels (0.7 ± 0.1 pmol/mg Cr, P = .07) tended to decrease in group I. In contrast, PGD-M levels increased dramatically in group II (61.3 ± 19.9 pmol/mg Cr, P < .05), whereas TX-M levels did not change. The decrease in FEV1 inversely correlated with basal urinary levels of both leukotriene E4 and PGD-M. Blood eosinophil and basophil levels increased and urinary PGD-M levels (2.2 ± 0.8 pmol/mg Cr, P < .001) decreased on 2 months of high-dose aspirin therapy in group I.

Conclusion: Failure to tolerate aspirin desensitization in a subset of patients with AERD is associated with prostaglandin D2 overproduction. The increase in blood eosinophil and basophil counts during high-dose aspirin therapy might reflect the functional consequences of decreased prostaglandin D2 release and the therapeutic benefit of aspirin.

Citing Articles

Unique effect of aspirin on local 15-oxo-eicosatetraenoic acid synthesis in asthma patients with aspirin hypersensitivity.

Szatkowski P, Gielicz A, Stepien A, Hartwich P, Kacorzyk R, Plutecka H Clin Transl Allergy. 2024; 14(12):e70004.

PMID: 39722441 PMC: 11669626. DOI: 10.1002/clt2.70004.

Low Prostaglandin E but High Prostaglandin D, a Paradoxical Dissociation in Arachidonic Acid Metabolism in Aspirin-Exacerbated Airway Disease: Role of Airway Epithelium.

Picado C, Machado-Carvalho L, Roca-Ferrer J J Clin Med. 2024; 13(23).

PMID: 39685875 PMC: 11642301. DOI: 10.3390/jcm13237416.

Nonsteroidal antiinflammatory drug-exacerbated respiratory disease: molecular mechanism, management and treatment.

Ley-Tomas J, Xicotencatl-Tellez A, Garcia-Cruz M, Jimenez-Chobillon M Front Allergy. 2024; 5:1462985.

PMID: 39665076 PMC: 11631927. DOI: 10.3389/falgy.2024.1462985.

New insights into the mechanisms of aspirin-exacerbated respiratory disease.

Laidlaw T Curr Opin Allergy Clin Immunol. 2024; 25(1):41-46.

PMID: 39641750 PMC: 11695142. DOI: 10.1097/ACI.0000000000001051.

Cysteinyl Leukotrienes in Allergic Inflammation.

Lee M, Boyce J, Barrett N Annu Rev Pathol. 2024; 20(1):115-141.

PMID: 39374430 PMC: 11759657. DOI: 10.1146/annurev-pathmechdis-111523-023509.

References

Liu T, Laidlaw T, Katz H, Boyce J . Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes. Proc Natl Acad Sci U S A. 2013; 110(42):16987-92. PMC: 3801005. DOI: 10.1073/pnas.1313185110. View

Swierczynska-Krepa M, Sanak M, Bochenek G, Strek P, Cmiel A, Gielicz A . Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study. J Allergy Clin Immunol. 2014; 134(4):883-90. DOI: 10.1016/j.jaci.2014.02.041. View

Higashi N, Taniguchi M, Mita H, Yamaguchi H, Ono E, Akiyama K . Aspirin-intolerant asthma (AIA) assessment using the urinary biomarkers, leukotriene E4 (LTE4) and prostaglandin D2 (PGD2) metabolites. Allergol Int. 2012; 61(3):393-403. DOI: 10.2332/allergolint.11-RA-0403. View

Szczeklik A, Gryglewski R, OLSZEWSKI E, Dembinska-Kiec A, Czerniawska-Mysik G . Aspirin-sensitive asthma: the effect of aspirin on the release of prostaglandins from nasal polyps. Pharmacol Res Commun. 1977; 9(5):415-25. DOI: 10.1016/s0031-6989(77)80027-1. View

Christie P, Tagari P, Ford-Hutchinson A, Charlesson S, Chee P, Arm J . Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis. 1991; 143(5 Pt 1):1025-9. DOI: 10.1164/ajrccm/143.5_Pt_1.1025. View

Kupczyk M, Kurmanowska Z, Kuprys-Lipinska I, Bochenska-Marciniak M, Kuna P . Mediators of inflammation in nasal lavage from aspirin intolerant patients after aspirin challenge. Respir Med. 2010; 104(10):1404-9. DOI: 10.1016/j.rmed.2010.04.017. View

Luo M, Jones S, Phare S, Coffey M, Peters-Golden M, Brock T . Protein kinase A inhibits leukotriene synthesis by phosphorylation of 5-lipoxygenase on serine 523. J Biol Chem. 2004; 279(40):41512-20. DOI: 10.1074/jbc.M312568200. View

Sousa A, Pfister R, Christie P, Lane S, Nasser S, Lee T . Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma. Thorax. 1998; 52(11):940-5. PMC: 1758450. DOI: 10.1136/thx.52.11.940. View

Lam B, Penrose J, Freeman G, Austen K . Expression cloning of a cDNA for human leukotriene C4 synthase, an integral membrane protein conjugating reduced glutathione to leukotriene A4. Proc Natl Acad Sci U S A. 1994; 91(16):7663-7. PMC: 44462. DOI: 10.1073/pnas.91.16.7663. View

10.

Kanaoka Y, Maekawa A, Austen K . Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand. J Biol Chem. 2013; 288(16):10967-72. PMC: 3630866. DOI: 10.1074/jbc.C113.453704. View

11.

Benyahia C, Gomez I, Kanyinda L, Boukais K, Danel C, Leseche G . PGE(2) receptor (EP(4)) agonists: potent dilators of human bronchi and future asthma therapy?. Pulm Pharmacol Ther. 2012; 25(1):115-8. DOI: 10.1016/j.pupt.2011.12.012. View

12.

Kumlin M, Stensvad F, Larsson L, Dahlen B, Dahlen S . Validation and application of a new simple strategy for measurements of urinary leukotriene E4 in humans. Clin Exp Allergy. 1995; 25(5):467-79. DOI: 10.1111/j.1365-2222.1995.tb01079.x. View

13.

Mastalerz L, Sanak M, Gawlewicz-Mroczka A, Gielicz A, Cmiel A, Szczeklik A . Prostaglandin E2 systemic production in patients with asthma with and without aspirin hypersensitivity. Thorax. 2007; 63(1):27-34. DOI: 10.1136/thx.2007.080903. View

14.

Busse W, Wenzel S, Meltzer E, Kerwin E, Liu M, Zhang N . Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients. J Allergy Clin Immunol. 2012; 131(2):339-45. DOI: 10.1016/j.jaci.2012.10.013. View

15.

Cheng K, Wu T, Wu K, Sturino C, Metters K, Gottesdiener K . Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A. 2006; 103(17):6682-7. PMC: 1458941. DOI: 10.1073/pnas.0601574103. View

16.

Beasley R, Featherstone R, Church M, Rafferty P, Varley J, Harris A . Effect of a thromboxane receptor antagonist on PGD2- and allergen-induced bronchoconstriction. J Appl Physiol (1985). 1989; 66(4):1685-93. DOI: 10.1152/jappl.1989.66.4.1685. View

17.

Welsch D, Creely D, Hauser S, Mathis K, Krivi G, Isakson P . Molecular cloning and expression of human leukotriene-C4 synthase. Proc Natl Acad Sci U S A. 1994; 91(21):9745-9. PMC: 44893. DOI: 10.1073/pnas.91.21.9745. View

18.

Macy E, Bernstein J, Castells M, Gawchik S, Lee T, Settipane R . Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper. Ann Allergy Asthma Immunol. 2007; 98(2):172-4. DOI: 10.1016/S1081-1206(10)60692-8. View

19.

Morrow J, Minton T . Improved assay for the quantification of 11-dehydrothromboxane B2 by gas chromatography-mass spectrometry. J Chromatogr. 1993; 612(2):179-85. DOI: 10.1016/0378-4347(93)80161-v. View

20.

Larsson A, Hagfjard A, Dahlen S, Adner M . Prostaglandin D₂ induces contractions through activation of TP receptors in peripheral lung tissue from the guinea pig. Eur J Pharmacol. 2011; 669(1-3):136-42. DOI: 10.1016/j.ejphar.2011.07.046. View